Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH3, is mediated by inhibition of cytokinesis

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 3, 2003, Pages 209-215

  Na, Hye Kyung ^a   Chang, Chia Cheng ^a   Trosko, James E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Anticancer, ras transformation; Cytokinesis; Tetraploidization

Indexed keywords

CYCLIN DEPENDENT KINASE 2; EDELFOSINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PROTEIN KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CELL POPULATION; CELL SIZE; CELL STRUCTURE; CELL TRANSFORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINESIS; DIPLOIDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; GENE ACTIVATION; GROWTH INHIBITION; LIVER CELL; MITOSIS INHIBITION; NONHUMAN; ONCOGENE H RAS; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0037364871     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0577-0     Document Type: Article

References (36)

1. Berkovic D (1998) Cytotoxic etherphospholipid analogues. Gen Pharmacol 31:511-517
2. Slaton JW, Hampton JA, Selman SH (1994) Exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. J Urol 152:1594-1598
3. Vogler WR, Liu J, Volpert O, Ades EW, Bouck N (1998) The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo. Cancer Invest 16:549-553
4. Baburina I, Jackowski S (1998) Apoptosis triggered by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine is prevented by increased expression of CTP: phosphocholine cytidylyltransferase. J Biol Chem 273:2169-2173
5. Gajate C, Santos-Beneit AM, Macho A, Lazaro M, Hernandez-De-Rojas A, Modolell M, Munoz E, Mollinedo F (2000) Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int J Cancer 86:208-218
6. Spiegel S, Olah Z, Cuvillier O, Edsall LC, Janoff AS (1999) Differential effects of free and liposome-associated 1-O-octadecyl-2-O-methylglycerophosphocholine on protein kinase C. FEBS Lett 454:137-141
7. Reed CB, Tang W, Ziboh VA (1991) Antineoplastic ether-linked phospholipid induces differentiation of acute myelogenous leukemic KG-1 cells into macrophage-like cells. Life Sci 49:1221-1227
8. Pushkareva MY, Janoff AS, Mayhew E (1999) Inhibition of cell division but not nuclear division by 1-O-octadecyl-2-O-methyl-Sn-glycero-3-phosphocholine. Cell Biol Int 23:817-828
9. Principe P, Sidoti C, Braquet P (1992) Tumor cell kinetics following antineoplastic ether phospholipid treatment. Cancer Res 52:2509-2515
10. Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, Martinez-Dalmau R, Modolell M (1997) Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res 57:1320-1328
11. Gajate C, Fonteriz RI, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, Modolell M, Mollinedo F (2000) Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 85:674-682
12. Gajate C, Santos-Beneit A, Modolell M, Mollinedo F (1998) Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Mol Pharmacol 53:602-612
13. 2+ signaling by antitumor ether lipid analogues. Cancer Res 50:4458-4463
14. Powis G, Seewald MJ, Gratas C, Melder D, Riebow J, Modest EJ (1992) Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res 52:2835-2840
15. Strassheim D, Shafer SH, Phelps SH, Williams CL (2000) Small cell lung carcinoma exhibits greater phospholipase C-betal expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res 60:2730-2736
16. Guo HB, Shen ZH, Huang CX, Ma J, Huang Y, Chen HL (2000) Modulation of the basal activity of phosphatidylinositol-3-kinase/protein kinase B signaling pathway in human hepatocarcinoma cells. Glycoconj J 17:315-322
17. Yart A, Laffargue M, Mayeux P, Chretien S, Peres C, Tonks N, Roche S, Payrastre B, Chap H, Raynal P (2001) A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem 276:8856-8864
18. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532
19. Yamamoto T, Taya S, Kaibuchi K (1999) Ras-induced transformation and signaling pathway. J Biochem (Tokyo) 126:799-803
20. Janowski M (1991) ras proteins and the ras-related signal transduction pathway. Radiat Environ Biophys 30:185-189
21. Campbell SL, Khosravi FR, Rossman KL, Clark GJ, Der CJ (1998) Increasing complexity of Ras signaling. Oncogene 17:1395-1413
22. Denhardt DT (1996) Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J 318:729-747
23. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97:3361-3369
24. Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ (2001) The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61:2289-2293
25. Fleischman LF, Chahwala SB, Cantley L (1986) ras-transformed cells: altered levels of phosphatidylinositol-4,5-bis-phosphate and catabolites. Science 231:407-410
26. Martin A, Duffy PA, Liossis C, Gomez MA, O'Brien L, Stone JC, Brindley DN (1997) Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblasts. Oncogene 14:1571-1580
27. Momchilova A, Markovska T (1999) Phosphatidylethanolamine and phosphatidylcholine are sources of diacylglycerol in ras-transformed NIH 3T3 fibroblasts. Int J Biochem Cell Biol 31:311-318
28. Hancock JF, Marshall CJ, McKay IA, Gardner S, Houslay MD, Hall A, Wakelam MJ (1988) Mutant but not normal p21 ras elevates inositol phospholipid breakdown in two different cell systems. Oncogene 3:187-193
29. Cullen PJ (2001) Ras effectors: buying shares in Ras plc. Curr Biol 11:R342-R344
30. Kelley GG, Reks SE, Ondrako JM, Smrcka AV (2001) Phospholipase C(epsilon): a novel Ras effector. EMBO J 20:743-754
31. de-Feijter AW, Ray JS, Weghorst CM, Klaunig JE, Goodman JI, Chang CC, Ruch RJ, Trosko JE (1990) Infection of rat liver epithelial cells with v-Ha-ras: correlation between oncogene expression, gap junctional communication, and tumorigenicity. Mol Carcinog 3:54-67
32. Fraker PJ, King LE, Lill-Elghanian D, Telford WG (1995) Quantification of apoptotic events in pure and heterogeneous populations of cells using the flow cytometer. Methods Cell Biol 46:57-76
33. Na HK, Wilson MR, Kang KS, Chang CC, Grunberger D, Trosko JE (2000) Restoration of gap junctional intercellular communication by caffeic acid phenylethyl ester (CAPE) in a ras-transformed rat liver epithelial cell line. Cancer Lett 157:31-38
34. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande-Woude GF, Ahn NG (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-970
35. Sun B, Murray NR, Fields AP (1997) A role for nuclear phosphatidylinositol-specific phospholipase C in the G2/M phase transition. J Biol Chem 272:26313-26317
36. Neri LM, Borgatti P, Capitani S, Martelli AM (1998) Nuclear diacylglycerol produced by phosphoinositide-specific phospholipase C is responsible for nuclear translocation of protein kinase C-alpha. J Biol Chem 273:29738-29744